Biweekly respiratory surveillance report for week ending January 10, 2026

Resources

For respiratory surveillance in Canada, visit: Respiratory Virus Detection Surveillance System and COVID-19 Data Trends
For surveillance of COVID-19 variants of concern, visit World Health Organization: Tracking SARS-CoV-2 Variants
For COVID-19 vaccination coverage in Canada, visit: COVID-19 vaccination in Canada

Key Highlights

COVID-19 activity is low and is decreasing
Influenza activity is moderate. Influenza A is decreasing and Influenza B is increasing
RSV activity is low and is decreasing

Disease summaries

The table below provides general trends from the different surveillance indicators for each disease that is included in this report.

Table 1. General trends from the different surveillance indicators for each disease in the Yukon

	COVID-19	Influenza	RSV
Percent positivity	Decreasing	Influenza A: Decreasing Influenza B: Increasing	Decreasing
Syndromic indicators		Stable
Case rates	Decreasing	Influenza A: Decreasing Influenza B: Increasing	Decreasing
Severity	Stable	Influenza A: Decreasing Influenza B: Increasing	Decreasing

Figure 1: Percent positivity by respiratory virus

Figure 2: Percent positivity and number of COVID-19 tests by pathogen and region

Percent Positivity

Volume of Tests

Figure 3: Percent positivity and number of Influenza A tests by region

Percent Positivity

Volume of Tests

Figure 4: Percent positivity and number of Influenza B tests by region

Percent Positivity

Volume of Tests

Figure 5: Percent positivity and number of RSV tests by region

Percent Positivity

Volume of Tests

Figure 6: COVID-19, Influenza A, Influenza B, and RSV wastewater surveillance - Whitehorse

Figure 8: Confirmed cases by respiratory virus

COVID-19

Overall

Rural communities

Whitehorse

Influenza A

Overall

Rural communities

Whitehorse

Influenza B

Overall

Rural communities

Whitehorse

RSV

Overall

Rural communities

Whitehorse

Figure 9: Confirmed case rates per 100,000 by respiratory virus

COVID-19

Overall